EPI-Q has successfully conducted thousands of RWE studies over 20 years, leading to improved patient outcomes, reduced costs, and more effective usage of pharmaceutical products.
Chicago, IL (PRWEB) June 03, 2014
What happens to a pharmaceutical product after it is approved? Is it meeting the clinical and safety expectations, and is it being used in the optimal patient populations in the most effective way? Real-world evidence (RWE) research is a fast-growing methodology used to provide essential information to health insurers, prescribers, patients, and manufacturers on a drug’s use, efficacy, and safety – after it’s approved and in use by the general patient population. RWE research is both costly and challenging to conduct, but the results, when derived from well-designed studies, can be extremely informative and improve patient health.
In a just-released podcast as part of HealthEconomics.Com’s CONNECTED COMMUNITY series, Dr. Mark Jewell, President of EPI-Q (https://www.epi-q.com), an international consulting firm based in Chicago, Illinois USA, provides keen insights using case studies as examples about how EPI-Q’s RWE studies have influenced health policy, informed treatment protocols, changed medication management strategies, reduced medical costs, enhanced employee work productivity, and improved patient outcomes. The full podcast, entitled “Secrets of Success: How EPI-Q Does Real-World Research that Really Makes a Difference” includes a one-on-one interview with Dr. Jewell by Dr. Patti Peeples, CEO and Founder of HealthEconomics.Com. A companion article containing additional insights by Jewell and EPI-Q on real-world research tools for success is available on HealthEconomics.Com’s tHEORetically Speaking blog, accessible here.
The podcast and blog focus on real-world evidence research in insomnia and chronic kidney disease, and feature a special section on challenges of conducting RWE in large private payers and new provider networks, such as Accountable Care Organizations (ACOs) and Integrated Delivery Networks (IDNs). Dr. Mark Jewell, President of EPI-Q, comments, “EPI-Q has conducted thousands of real-world evidence research studies over the past 20 years in multiple therapeutic areas, including insomnia, cancer, diabetes, chronic pain, rheumatology, nephrology, and cardiology, among others. As evidence of the quality and impact of our research, EPI-Q’s study results have been featured in the national media, including CNN, CBS News, and US News and World Report, and more than 95% of all EPI-Q manuscripts have been published in esteemed peer-reviewed medical and healthcare journals across the globe.” The staff at EPI-Q include epidemiologists, economists, statisticians, physicians, pharmacists, nurses, and quality improvement experts, with advanced training in healthcare research methodology.
Patti Peeples, PhD, of HealthEconomics.Com said, “Mark Jewell provided some fresh and innovative insights into how EPI-Q conducts real-world research in the newer healthcare delivery systems, such as ACOs, that are increasingly more common in the United States. Today, insurance payers are demanding evidence on pharmaceutical product use in the real-world, in addition to data from controlled clinical trials. Companies like EPI-Q that have a breadth of experience in therapeutic areas and healthcare system environments, and who can work with the pioneering health information technology platforms, are important players in our nation’s movement toward improving health outcomes and reducing cost.” The CONNECTED COMMUNITY Podcast series from HealthEconomics.Com has featured a variety of experts in the pharmaceutical health outcomes arena, and the full list of interviews may be accessed here.
EPI-Q (https://www.epi-q.com) is an international consulting firm providing high-quality research demonstrating clinical and economic benefits of medical therapies and technologies, thereby enhancing the quality of clinical practice and patient care. EPI-Q drives the development of evidence and value propositions to support product commercialization, facilitate market access, and optimize pricing and reimbursement. EPI-Q is a global organization with headquarters in Chicago, Illinois USA and a network of strategic partners throughout Europe, India, Latin America, and other emerging markets.
A pioneer in the field, HealthEconomics.Com (http://www.healtheconomics.com) is the top-ranked global link to pharmaceutical market access, health economics, and outcomes research. Offering a CONNECTED COMMUNITY for professionals involved in health economics, outcomes research, market access, health policy, reimbursement, and pricing, HealthEconomics.Com provides professionals with multiple ways to connect to news, policy updates, resources, events, and jobs via a popular website, newsletter service, virtual conference arena, blog, extensive social media platforms, and a webinar and podcast service. News Media interested in receiving the most current information on healthcare value and market access may access for free any resources and news on HealthEconomics.Com by visiting the website or by subscribing to multiple HealthEconomics.Com Newsletters.